Mizuho raises Enliven Therapeutics stock target to $41

On Friday, Mizuho (NYSE:MFG) Securities analyst Salim Syed increased the price target on Enliven Therapeutics (NASDAQ:ELVN) to $41.00, up from $39.00, while reiterating an Outperform rating on the company’s shares. The new target represents significant upside potential from the current price of $17.74. Syed’s evaluation follows Enliven’s first-quarter financial results for 2025. The analyst believes that Enliven Therapeutics is a significantly underappreciated company within their coverage and potentially in the broader market, a view supported by InvestingPro data showing analyst targets ranging from $27 to $45.

Syed praised Enliven for its "validated science" and the company’s positioning in the chronic myeloid leukemia (CML) treatment market, which has a total addressable market (TAM) estimated at $12-14 billion. The company’s strong financial position is evident through InvestingPro data, showing more cash than debt on its balance sheet and an impressive current ratio of 21.06. The analyst also highlighted Enliven’s robust data and experienced management team, which includes veterans from Array BioPharma, a company previously acquired by Pfizer (NYSE:PFE) for $11.4 billion.

The analyst anticipates further insights about the company’s progress at the upcoming European Hematology Association (EHA) meeting scheduled for June 13, 2025. Expectations for the meeting are aligned with the abstract, but with additional patient numbers and follow-up data anticipated. According to Syed, the forthcoming data could potentially increase investor interest in Enliven Therapeutics’ stock.

Moreover, Syed suggested that if the public markets do not recognize the company’s value, the likelihood of acquisition interest from large-cap strategic companies could increase. With a market capitalization of $870.49 million and a beta of 1.1, Enliven’s oncology asset is perceived as lower-risk and suitable for long-term treatment, making it an attractive addition to the portfolios of larger pharmaceutical companies. For deeper insights into Enliven’s valuation metrics and growth potential, investors can access additional analysis through InvestingPro, which features 5 more exclusive ProTips about the company.

In other recent news, Enliven Therapeutics has reported promising results from its Phase 1 clinical trial of ELVN-001, a treatment for chronic myeloid leukemia (CML). The trial, which involved 74 patients, showed that 44% of evaluable patients achieved a major molecular response by 24 weeks, with a favorable safety profile. The company plans to present these findings at the European Hematology Association 2025 Congress. Additionally, BTIG analyst Justin Zelin raised the firm’s price target for Enliven Therapeutics to $45, citing the positive trial data and strategic focus on ELVN-001. Zelin’s analysis also noted a higher probability of success for ELVN-001 in treating CML. Meanwhile, H.C. Wainwright analyst Robert Burns increased the price target to $40, maintaining a Buy rating on the stock. Enliven’s first-quarter financials showed a net loss of $0.57 per share, aligning with expectations, and the company ended the quarter with $289.6 million in cash, expected to fund operations into late 2027. Enliven is also seeking strategic alternatives for its HER2 TKI program, ELVN-002, as it shifts focus to ELVN-001.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.